AbbVie Earnings
AbbVie lowered its full-year earnings guidance following costs associated with its Apogee acquisition.
AbbVie lowered its full-year 2026 adjusted earnings per share guidance to a range of $13.87 to $14.07, down from its prior projection of $13.91 to $14.11. Guidance cuts reduce future corporate cash flow expectations, which directly lowers the price investors are willing to pay for a stock today. Consequently, AbbVie shares fell $9.51, or 3.69 percent, to $248.00 in pre-market trading. The reduction stems from its proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in 2026 assuming a third-quarter close, alongside $0.58 per share in acquired R&D expenses. This dilution impacts equity investors while offsetting $0.10 of operational overperformance. No dissenting analyst views were reported. This reading would be proven wrong if full-year adjusted earnings print above $14.11 per share.